| CAK | CDK-activating kinase |
| CDK | Cyclin-dependent kinase |
| CDKN2A | Cyclin-dependent kinase Inhibitor 2A |
| CLL | Chronic lymphocytic leukemia |
| CMGC | CDKs, MAPKs, Gsk3β, and CDK-like kinases |
| CTD | C-Terminal Domain |
| DYRK | Dual-specificity tyrosine-regulated kinase |
| ELL2 | Elongation Factor for RNA Polymerase II |
| FACT protein | Facilitates chromatin transcription |
| FDA | US Food and Drug Administration |
| FOLFIRINOX | FOL = Folinic acid, L = Leucovorin, F = 5-FU = 5-Fluorouracil, IRIN = Irinotecan, OX = Oxaliplatin |
| FoxM1 | Forkhead box protein M1 |
| GADD45 | Growth Arrest and DNA Damage-inducible protein |
| GSK3β | Glycogen synthase kinase-3 β |
| hESC | Human embryonic stem cells |
| hiPSC | Human induced pluripotent stem cells |
| INK4 | Inhibitor of Cyclin-Dependent Kinase 4 |
| MAPK | Mitogen-activated protein kinase |
| MAT1 | Menage á trois 1 |
| Mcl-1 | Myeloid leukaemia cell differentiation protein 1 |
| MED12 | Mediator complex subunit 12 |
| MED13 | Mediator complex subunit 13 |
| MPK7 | Mitogen-activated protein kinase 7 |
| mTOR | Mechanistic target of rapamycin |
| NSCLC | Non-small cell lung cancer |
| PanIN | Pancreatic intraepithelial neoplasia |
| PDAC | Pancreatic ductal adenocarcinoma |
| pTEFb | Positive transcription elongation factor b |
| RalA | RAS-Like Protein A |
| Rb | Retinoblastoma protein |
| RNA Pol II | RNA polymerase II |
| ROS | Reactive oxygen species |
| TAK | Tat-associated kinase |
| TCF/LEF | T-cell factor/lymphoid enhancer factor |
| TF | Transcription factor |
| TFIIH | Transcription factor II H |
| TP53 | Tumour protein p53 |
| TPKII | Tau protein kinase II |
| TRAIL-R1/2 | Tumour necrosis factor-related, apoptosis-inducing ligand receptors 1/2 |